ATE195077T1 - Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern - Google Patents

Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern

Info

Publication number
ATE195077T1
ATE195077T1 AT94907503T AT94907503T ATE195077T1 AT E195077 T1 ATE195077 T1 AT E195077T1 AT 94907503 T AT94907503 T AT 94907503T AT 94907503 T AT94907503 T AT 94907503T AT E195077 T1 ATE195077 T1 AT E195077T1
Authority
AT
Austria
Prior art keywords
pct
vaccines
antigens
topical administration
mammals
Prior art date
Application number
AT94907503T
Other languages
English (en)
Inventor
Sveinbjoern Gizurarson
Iver Heron
Original Assignee
Lyfjathroun H F
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun H F, Statens Seruminstitut filed Critical Lyfjathroun H F
Application granted granted Critical
Publication of ATE195077T1 publication Critical patent/ATE195077T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94907503T 1993-02-15 1994-02-14 Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern ATE195077T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
PCT/DK1994/000062 WO1994017827A1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane

Publications (1)

Publication Number Publication Date
ATE195077T1 true ATE195077T1 (de) 2000-08-15

Family

ID=8090567

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94907503T ATE195077T1 (de) 1993-02-15 1994-02-14 Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern

Country Status (14)

Country Link
US (1) US5942237A (de)
EP (1) EP0682528B1 (de)
JP (1) JPH09508614A (de)
AT (1) ATE195077T1 (de)
AU (1) AU668290B2 (de)
CA (1) CA2156084A1 (de)
DE (1) DE69425427T2 (de)
DK (2) DK17093D0 (de)
ES (1) ES2150982T3 (de)
GR (1) GR3034727T3 (de)
NO (1) NO312057B1 (de)
OA (1) OA10564A (de)
PT (1) PT682528E (de)
WO (1) WO1994017827A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
ES2185900T3 (es) * 1996-01-25 2003-05-01 Profylakse Aps Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos.
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
CA2325939A1 (en) * 1998-04-09 1999-10-21 Martin Friede Vaccine
US7229621B2 (en) * 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
EP1034792A1 (de) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasale Verabreichung von Pneumokokken-Polysaccharid Impfstoffen
EP1214054B1 (de) * 1999-09-24 2007-10-31 GlaxoSmithKline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
JP2005509598A (ja) * 2001-08-16 2005-04-14 リュフヤトルン・エイチエフ，バイオファーマシューティカルズ エクスビボで抗体を産生する方法
KR100406503B1 (ko) * 2001-09-25 2003-11-19 한국과학기술연구원 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
WO2003070280A2 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
BR0215954A (pt) * 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
US20070184058A1 (en) * 2003-02-27 2007-08-09 Yaron Ilan Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
AU2005329255B2 (en) 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
CA2596920C (en) 2005-01-28 2015-05-05 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
US20070054834A1 (en) * 2005-04-11 2007-03-08 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
EP1951200A2 (de) * 2005-08-09 2008-08-06 Nanobio Corporation Eine nanoemulsion enthaltende zusammensetzungen mit entzündungshemmender wirkung
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
EP2139993A2 (de) * 2007-04-27 2010-01-06 Dow Global Technologies Inc. Verbesserte herstellung und in-vivo-synthese löslicher und rekombinanter virusähnlicher partikel in ikosaeder-form
AU2009248810B2 (en) * 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
CN106974888B (zh) * 2008-09-17 2019-08-02 克艾思马有限公司 药物组合物和相关的给药方法
CA2765511C (en) * 2009-06-16 2015-05-12 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3064218B1 (de) 2013-10-31 2019-06-19 Hisamitsu Pharmaceutical Co., Inc. Adjuvantienzusammensetzung
US10525088B2 (en) 2014-05-30 2020-01-07 Kirin Holdings Kabushiki Kaisha Lactic acid bacterial immunopotentiating activity-increasing composition and method for increasing immunopotentiating activity of lactic acid bacteria
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN111721937B (zh) * 2019-03-29 2023-04-07 北京九强生物技术股份有限公司 人附睾蛋白4免疫比浊试剂盒
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
DE3446515A1 (de) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg Oeladjuvierte vaccine und verfahren zu ihrer herstellung
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
NL9000207A (de) * 1990-01-29 1991-08-16 Duphar Int Res
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
PT534618E (pt) * 1991-08-26 2006-08-31 Scripps Research Inst Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b
CA2083553A1 (en) * 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition

Also Published As

Publication number Publication date
EP0682528A1 (de) 1995-11-22
PT682528E (pt) 2001-01-31
DK0682528T3 (da) 2000-12-27
CA2156084A1 (en) 1994-08-18
GR3034727T3 (en) 2001-01-31
DE69425427D1 (de) 2000-09-07
JPH09508614A (ja) 1997-09-02
DK17093D0 (da) 1993-02-15
ES2150982T3 (es) 2000-12-16
NO312057B1 (no) 2002-03-11
NO953182L (no) 1995-10-12
OA10564A (en) 2002-06-20
NO953182D0 (no) 1995-08-14
AU668290B2 (en) 1996-04-26
WO1994017827A1 (en) 1994-08-18
DE69425427T2 (de) 2001-02-08
EP0682528B1 (de) 2000-08-02
AU6106594A (en) 1994-08-29
US5942237A (en) 1999-08-24

Similar Documents

Publication Publication Date Title
ATE195077T1 (de) Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
ES2150022T3 (es) Aerosol farmaceutico que contiene al menos un azucar.
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
ITMI922699A1 (it) Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
IT8619675A0 (it) Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale.
TR200100569T2 (tr) Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
DK0613371T3 (da) Ny kombination af formoterol og budesonid
YU28392A (sh) Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a
TR200100628T2 (tr) Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler.
ES2079485T3 (es) Composiciones farmaceuticas y un dispositivo para administrar las mismas.
ATE86858T1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
UA27848C2 (uk) Лікарська форма, що перорально вводиться, для лікування центральних станів дефіциту допаміну
NO922936L (no) Fremstilling av fettsyremedikamenter
IT8821324A0 (it) Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
ATE50260T1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
Katz et al. Burning mouth sensation associated with fusospirochetal infection in edentulous patients
NO951982L (no) Mucosal tilförsel av pneumokokkiske antigener
FI963394A0 (fi) Yskää vastustava koostumus, joka sisältää yskää vastustavaa ainetta ja bentsydamiinia
Klawans et al. Neuroleptic-induced tardive dyskinesias in nonpsychotic patients
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
ATE121298T1 (de) Verfahren zur herstellung eines antikaries- impfstoffes aus streptococcus mutans und impfzusammensetzung gegen karies in form von nasentropfen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee